Consistent with this, examination of T cells from AML patients at diagnosis also revealed that a higher frequency of T cells in the RAS mutant AML tumor microenvironment display gene expression of PD-1 in comparison to MLL translocated AML, suggesting that RAS mutant AML can only progress in the context of inhibitory receptor expression on T cells. The gene discussed is KMT2A; the disease is acute myeloid leukemia.